No Data
Express News | Hillevax: Completed Workforce Reduction of About 15 Employees Constituting About 25% of Co’s Workforce
What Makes HilleVax (HLVX) a New Buy Stock
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Oral vaccines have broad prospects. O'Brien, Homer, gives Vaxart (vaxart.US) an 'outperform' rating against the large cap market.
Initiating coverage on Vaxart (VXRT.US) with an outperform rating and target price of $4, which is expected to outperform the overall market.
Oppenheimer Starts Vaxart at Outperform, Cites Oral Vaccine Focus
HilleVax, Inc.: Prudent Cost Management Amidst Trial Setbacks – Hold Rating Justified
No Data
No Data